IXICO plc Appointment of Independent Non-Executive Director (7310O)

TIDMIXI

RNS Number : 7310O

IXICO plc

05 October 2023

5 October 2023

IXICO plc

("IXICO" or the "Company")

Appointment of Independent Non-Executive Director

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, is pleased to announce the appointment of Dr Dipti Amin as an Independent Non-Executive Director of the Company with immediate effect.

Dr Amin is an experienced non-executive director and medically trained senior executive with extensive commercial, leadership and operational experience, in medicine, pharmacology and the highly regulated healthcare and research sectors.

Dr Amin spent over twenty years of her executive career at IQVIA, occupying senior positions in compliance, drug safety and medical affairs and will bring significant additional pharmaceutical and CRO experience to the Company.

Dr Amin currently sits on the Boards of the University of Hertfordshire and Lineage Cell Therapeutics, a US based biotechnology company, having previously sat on the Boards of companies in both the private and public sectors.

Dr Amin will also be joining the Remuneration and Audit committees with immediate effect.

Charles Spicer, Chair of IXICO, commented:

"We are delighted to welcome Dipti to our Board and look forward to benefitting from her broad and deep experience of both the pharmaceutical and CRO sectors."

 
 For further information please contact: 
   IXICO plc                                                        [phone] 
   Giulio Cerroni, Chief Executive Officer 
    Grant Nash, Chief Financial Officer 
 
   Cavendish Securities PLC (Nominated adviser and sole broker)     [phone] 
   Giles Balleny / Charlie Combe (Corporate 
    Finance) 
   Michael F Johnson / Tamar Cranford 
    Smith (Sales) 
 
 
 
 
  About IXICO 
  IXICO is dedicated to delivering insights in neuroscience to 
  help transform the advancement of investigational therapies 
  for neurological diseases, such as Huntington's disease, Parkinson's 
  disease and Alzheimer's disease. The Company's purpose is to 
  advance medicine and human health by turning data into clinically 
  meaningful information, providing valuable new insights in neuroscience 
  by supporting pharmaceutical companies across all phases of 
  CNS clinical research. IXICO's goal is to be a leading advocate 
  of artificial intelligence in medical image analysis. 
 
  IXICO has developed and deployed breakthrough data analytics, 
  at scale, through its remote access technology platform, to 
  improve the return on investment in drug development and reduce 
  risk and uncertainty in clinical trials for the Company's pharmaceutical 
  clients. 
 
  More information is available on www.IXICO.com and follow us 
  on Twitter @IXICOnews 
 
 
 
  Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Dipti 
  Mahendra Amin (Patel), aged 59, holds or has held the following 
  directorships or partnerships in the past five years: 
   Current                        Previous 
   Lineage Cell Therapeutics      Buckinghamshire Healthcare 
    University of Hertfordshire    NHS Trust Cambridge Innovation 
                                   Capital Limited 
                                   Maaya Associates Limited 
                                 -------------------------------- 
 
 
 
  Dr Amin does not currently hold any shares in the Company. 
 
  There is no further information required to be disclosed in 
  respect of the above appointment pursuant to Rule 17 and Schedule 
  2 (g) of the AIM Rules for Companies. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUPGRPUUPWGQC

(END) Dow Jones Newswires

October 05, 2023 02:00 ET (06:00 GMT)